Pulmonary Fibrosis/ Interstitial Lung Disease
The Idiopathic Pulmonary Fibrosis Program at UAB
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by the presence of "usual interstitial pneumonia" (UIP) in the lung parenchyma. The causes of IPF remain largely unknown and, to this day, no drug is able to halt the fibrosing process or prolong the survival of patients with this disease. Selected patients may benefit from lung transplantation. In Europe, IPF is known as "chronic fibrosing alveolitis" (CFA).
The UAB/HSF Idiopathic Pulmonary Fibrosis Program has the following objectives
- Provide state of the art, comprehensive evaluation and treatment of patients with IPF;
- Participate in multicenter studies on new drugs and other novel therapeutic modalities for IPF;
- Foster close collaboration between clinicians and basic scientists and, in doing so, generate new insights into the mechanisms of IPF.
The Idiopathic Pulmonary Fibrosis Program at UAB/The Kirklin Clinic
THT 215, 1900 University Boulevard Birmingham, AL 35294-0006
Phone (205) 934-7557
Fax (205) 934-6229
The IPF Program at UAB Staff
Joao A. de Andrade, M.D.
Assistant Professor of Medicine
Director and Principal Investigator
Joseph B. Barney, M.D.
Instructor in Medicine
Tonja Meadows, R.N.
Research and Clinical Coordinator
L. Kay Westwater
Office Administrator
Co-Investigators and Consultants
C. Bruce Alexander, M.D.
Professor of Pathology
Robert J. Cerfolio, M.D.
Associate Professor of Surgery
Hrudaya “Bobby” Nath, M.D.
Professor of Radiology
Colleen Sanders, M.D.
Associate Professor of Radiology